Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06002945 · ClinicalTrials.gov registry record

Exploring Outcomes and Characteristics of Myasthenia Gravis 2

A clinical trial of Myasthenia Gravis, sponsored by Yale University.

Active
Registry status
400
Enrollment target
10
Study locations

NCT06002945 is a study of Myasthenia Gravis that is active but no longer recruiting, run by Yale University. The registered enrollment target is 400 participants, above the 179-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (123% higher). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06002945, a study of Myasthenia Gravis, is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
400 participants
Enrollment target
10
Study locations

Study Summary

The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

Conditions Studied

Interventions

  • OTHER Blood sample

Study Locations (10)

North Carolina

  • University of North Carolina - Chapel Hill
  • Duke University Medical Center - Durham
  • Wake Forest University - Winston-Salem

California

  • University of California-Irvine - Irvine
  • Cedars Sinai Medical Center - Los Angeles

Connecticut

  • Yale University - New Haven

District of Columbia

  • George Washington University - Washington D.C.

Illinois

  • University of Chicago - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2021-01-12
Est. Completion 2026-12

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT06002945

The ClinicalTrials.gov registry entry for NCT06002945 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (123% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Blood sample is the first listed.

NCT06002945 reports 10 study locations spanning 7 distinct geographic areas - top geographies include North Carolina, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06002945 about?

NCT06002945 is a clinical study titled "Exploring Outcomes and Characteristics of Myasthenia Gravis 2". The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

What is the current status of trial NCT06002945?

This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-01-12. Estimated completion is 2026-12.

What conditions does trial NCT06002945 study?

This clinical trial studies the following conditions: Myasthenia Gravis.

What interventions are being tested in trial NCT06002945?

The interventions under investigation include: Blood sample (OTHER).

Who is sponsoring clinical trial NCT06002945?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06002945 being conducted?

This trial has 10 study locations across California, Connecticut, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.